{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:19:08Z","timestamp":1787239148612,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15384-2","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T20:57:16Z","timestamp":1764449836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence and factors associated with chemotherapy-induced adverse events in cancer treatment centers in Amhara national regional state comprehensive referral hospitals, 2024: multicenter prospective follow up study"],"prefix":"10.1186","volume":"26","author":[{"given":"Atalay Eshetie","family":"Demilie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habtu Tsehayu","family":"Bayu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahder Metenu","family":"Taye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fikadu Tadesse","family":"Diress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endale Gebreegziabher","family":"Gebremedhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"issue":"1","key":"15384_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrc1529","volume":"5","author":"BA Chabner","year":"2005","unstructured":"Chabner BA, Roberts TG. Chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5(1):65\u201372.","journal-title":"Nat Rev Cancer"},{"key":"15384_CR2","first-page":"1023","volume":"15","author":"K Jordan","year":"2007","unstructured":"Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf H-H, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 2007;15:1023\u201333.","journal-title":"Support Care Cancer"},{"key":"15384_CR3","doi-asserted-by":"crossref","unstructured":"Aslam MS, Naveed S, Ahmed A, Abbas Z, Gull I, Athar MA. Side effects of chemotherapy in cancer patients and evaluation of patients opinion about starvation based differential chemotherapy. Journal of Cancer Therapy. 2014.","DOI":"10.4236\/jct.2014.58089"},{"issue":"12","key":"15384_CR4","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1517\/17425250903451675","volume":"5","author":"KK Sankhala","year":"2009","unstructured":"Sankhala KK, Pandya DM, Sarantopoulos J, Soefje SA, Giles FJ, Chawla SP. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol. 2009;5(12):1607\u201314.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"15384_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jpainsymman.2006.10.015","volume":"34","author":"SC Teunissen","year":"2007","unstructured":"Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manag. 2007;34(1):94\u2013104.","journal-title":"J Pain Symptom Manag"},{"key":"15384_CR6","doi-asserted-by":"crossref","unstructured":"Flemm LA. Aprepitant for chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2004;8(3).","DOI":"10.1188\/04.CJON.303-306"},{"issue":"3","key":"15384_CR7","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/1097-0142(19890201)63:3<604::AID-CNCR2820630334>3.0.CO;2-2","volume":"63","author":"RR Love","year":"1989","unstructured":"Love RR, Leventhal H, Easterling DV, Nerenz DR. Side effects and emotional distress during cancer chemotherapy. Cancer. 1989;63(3):604\u201312.","journal-title":"Cancer"},{"issue":"1","key":"15384_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1586\/17512433.1.1.27","volume":"1","author":"J LaRusso","year":"2008","unstructured":"LaRusso J, Waldman SA, Kraft WK. Aprepitant for the prevention of nausea and vomiting associated with chemotherapy and postoperative recovery. Expert Rev Clin Pharmacol. 2008;1(1):27\u201337.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"15384_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/pbc.21835","volume":"52","author":"LY Ramirez","year":"2009","unstructured":"Ramirez LY, Huestis SE, Yap TY, Zyzanski S, Drotar D, Kodish E. Potential chemotherapy side effects: what do oncologists tell parents? Pediatr Blood Cancer. 2009;52(4):497\u2013502.","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"15384_CR10","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1517\/14656566.4.12.2279","volume":"4","author":"L Patel","year":"2003","unstructured":"Patel L, Lindley C. Aprepitant\u2013a novel NK1-receptor antagonist. Expert Opin Pharmacother. 2003;4(12):2279\u201396.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"15384_CR11","first-page":"803","volume":"6","author":"-SS Nabila El","year":"2019","unstructured":"Nabila El -SS, Amal A, el, Amal A, El-A, Fathyia S. Effect of nursing intervention for chemotherapy induced nausea and vomiting among breast cancer women. Int J Novel Res Healthc Nurs. 2019;6(1):803\u201317.","journal-title":"Int J Novel Res Healthc Nurs"},{"issue":"8","key":"15384_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/ajhp\/56.8.729","volume":"56","author":"DCS","year":"1999","unstructured":"DCS. ASHP therapeutic guidelines on the Pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-System Pharm. 1999;56(8):729\u201364.","journal-title":"Am J Health-System Pharm"},{"key":"15384_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4828563","author":"PJS Endale Gebreegziabher Gebremedhn","year":"2019","unstructured":"Endale Gebreegziabher Gebremedhn PJS, David Anthony Mahns. Variability of Oxaliplatin-Induced neuropathic pain symptoms in each cycle and its implications on the management of colorectal cancer patients: A retrospective study in South Western Sydney local health district Hospitals, Sydney, Australia. J Oncol. 2019. https:\/\/doi.org\/10.1155\/2019\/4828563.","journal-title":"J Oncol"},{"key":"15384_CR14","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12885-018-4185-0","volume":"18","author":"G Endale","year":"2018","unstructured":"Endale G, David AM. The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review. BMC Cancer. 2018;18:410.","journal-title":"BMC Cancer"},{"key":"15384_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/DHPS.S116924","volume":"8","author":"SA Belachew","year":"2016","unstructured":"Belachew SA, Erku DA, Mekuria AB, Gebresillassie BM. Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar university referral Hospital, ethiopia: a cross-sectional study. Drug Healthc Patient Saf. 2016;8:83\u201390.","journal-title":"Drug Healthc Patient Saf"},{"issue":"1","key":"15384_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1207\/S15327914NC3701_1","volume":"37","author":"KA Conklin","year":"2000","unstructured":"Conklin KA. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer. 2000;37(1):1\u201318.","journal-title":"Nutr Cancer"},{"issue":"11","key":"15384_CR17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41571-022-00685-3","volume":"19","author":"NM Kuderer","year":"2022","unstructured":"Kuderer NM, Desai A, Lustberg MB, Lyman GH. Mitigating acute chemotherapy-associated adverse events in patients with cancer. Nat Reviews Clin Oncol. 2022;19(11):681\u201397.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"4","key":"15384_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/bcp.14159","volume":"86","author":"I Ingrand","year":"2020","unstructured":"Ingrand I, Defossez G, Lafay-Chebassier C, Chavant F, Ferru A, Ingrand P, et al. Serious adverse effects occurring after chemotherapy: A general cancer registry-based incidence survey. Br J Clin Pharmacol. 2020;86(4):711\u201322.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"15384_CR19","doi-asserted-by":"publisher","first-page":"e0184360","DOI":"10.1371\/journal.pone.0184360","volume":"12","author":"A Pearce","year":"2017","unstructured":"Pearce A, Haas M, Viney R, Pearson SA, Haywood P, Brown C, et al. Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. PLoS ONE. 2017;12(10):e0184360.","journal-title":"PLoS ONE"},{"issue":"1","key":"15384_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jpainsymman.2006.10.015","volume":"34","author":"SCCM Teunissen","year":"2007","unstructured":"Teunissen SCCM, Wesker W, Kruitwagen C, de Haes HCJM, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: A systematic review. J Pain Symptom Manag. 2007;34(1):94\u2013104.","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"15384_CR21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S1471-4892(02)00227-8","volume":"2","author":"PLR Andrews","year":"2002","unstructured":"Andrews PLR, Sanger GJ. Abdominal vagal afferent neurones: an important target for the treatment of Gastrointestinal dysfunction. Curr Opin Pharmacol. 2002;2(6):650\u20136.","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"15384_CR22","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155(12):2461\u201370.","journal-title":"Pain"},{"issue":"7","key":"15384_CR23","first-page":"5","volume":"15","author":"R Tr\u00fceb","year":"2010","unstructured":"Tr\u00fceb R. Chemotherapy-induced hair loss. Skin Therapy Lett. 2010;15(7):5\u20137.","journal-title":"Skin Therapy Lett"},{"issue":"13","key":"15384_CR24","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.21.02377","volume":"40","author":"JM Unger","year":"2022","unstructured":"Unger JM, Vaidya R, Albain KS, LeBlanc M, Minasian LM, Gotay CC, et al. Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J Clin Oncol. 2022;40(13):1474\u201386.","journal-title":"J Clin Oncol"},{"key":"15384_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2934-5","volume":"16","author":"SH Seo","year":"2016","unstructured":"Seo SH, Kim S-E, Kang Y-K, Ryoo B-Y, Ryu M-H, Jeong JH, et al. Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients. BMC Cancer. 2016;16:1\u20139.","journal-title":"BMC Cancer"},{"issue":"10","key":"15384_CR26","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1200\/JCO.1984.2.10.1170","volume":"2","author":"GR Morrow","year":"1984","unstructured":"Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol. 1984;2(10):1170\u20136.","journal-title":"J Clin Oncol"},{"issue":"8","key":"15384_CR27","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/14656566.2017.1317746","volume":"18","author":"Y Tsuji","year":"2017","unstructured":"Tsuji Y, Baba H, Takeda K, Kobayashi M, Oki E, Gotoh M, et al. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. Expert Opin Pharmacother. 2017;18(8):753\u20138.","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"15384_CR28","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/s41416-018-0037-6","volume":"118","author":"JW Kim","year":"2018","unstructured":"Kim JW, Lee Y-G, Hwang IG, Song HS, Koh SJ, Ko YH, et al. Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean cancer study group (KCSG) multicentre prospective study. Br J Cancer. 2018;118(9):1169\u201375.","journal-title":"Br J Cancer"},{"issue":"10","key":"15384_CR29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.18553\/jmcp.2015.21.10.863","volume":"21","author":"N Rashid","year":"2015","unstructured":"Rashid N, Koh HA, Baca HC, Li Z, Malecha S, Abidoye O, et al. Clinical impact of chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. J Managed Care Specialty Pharm. 2015;21(10):863\u2013b71.","journal-title":"J Managed Care Specialty Pharm"},{"issue":"1","key":"15384_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.clnu.2015.11.008","volume":"36","author":"M Motoori","year":"2017","unstructured":"Motoori M, Yano M, Miyata H, Sugimura K, Saito T, Omori T, et al. Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. Clin Nutr. 2017;36(1):93\u20139.","journal-title":"Clin Nutr"},{"issue":"3","key":"15384_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1742-7843.2007.00122.x","volume":"101","author":"J Herrstedt","year":"2007","unstructured":"Herrstedt J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol. 2007;101(3):143\u201350.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"03","key":"15384_CR32","doi-asserted-by":"publisher","first-page":"334","DOI":"10.4103\/ijmpo.ijmpo_116_17","volume":"38","author":"G Baburaj","year":"2017","unstructured":"Baburaj G, Abraham AM, George L, Shetty V, Thempalangad RM, Rajesh K, et al. A study on utilization and evaluation of antiemetics in chemotherapy\u2013induced nausea and vomiting. Indian J Med Pediatr Oncol. 2017;38(03):334\u20139.","journal-title":"Indian J Med Pediatr Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15384-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15384-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15384-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:03:22Z","timestamp":1767837802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15384-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15384"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15384-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"11 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethical review committee of School of Medicine, Bahir Dar University ethical review committee with ethical registration number 003\/2024) and official permission letter was obtained from Tibebe Ghion and Felege hiwot hospitals. All methods in this study were carried out in accordance with relevant guidelines and regulations .The patients provided written informed consent prior to participate in the study and were able to withdraw from the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}